Displaying 881 - 900 of 4737
2102007 Informal Interpretation
FTC Report Cites Benefits of International Cooperation On Antitrust and Consumer Protection Enforcement
Concurring Statement of Acting Chairwoman Rebecca Kelly Slaughter joined by Commissioner Rohit Chopra regarding the Revised Clayton Act Thresholds
FTC Announces Annual Update of Size of Transaction Thresholds for Premerger Notification Filings and Interlocking Directorates
2102001 Informal Interpretation
FTC, DOJ Temporarily Suspend Discretionary Practice of Early Termination
Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding the Commission's Indefinite Suspension of Early Terminations
Following Federal Trade Commission Staff Recommendation to Challenge Transaction, Tronox Holding plc. Abandons Proposed Acquisition of TiZir Titanium and Iron
FTC Approves Final Order Imposing Conditions on Combination of Pfizer Inc.’s Upjohn and Mylan N.V.
Pfizer/Mylan, In the Matter of
Pharmaceutical companies Pfizer Inc. and Mylan N.V. have agreed to divest assets and abide by other conditions to settle Federal Trade Commission charges that the proposed combination of Upjohn Inc. and Mylan N.V. will harm current or future competition in ten generic drug markets. The FTC’s complaint alleges that the proposed combination would harm current U.S. competition in seven product markets by reducing the number of existing suppliers, and that it would harm future U.S. competition in three additional product markets. The proposed consent order requires divestitures in all 10 markets.
2101004 Informal Interpretation
FTC Again Charges Endo and Impax with Illegally Preventing Competition in U.S. Market for Oxymorphone ER
2101002 Informal Interpretation
FTC Publishes Annual Performance Report
Displaying 881 - 900 of 4737